Abstract
Selective RET inhibitors has been approved for RET fusion non-small cell lung cancer (NSCLC) after failure of platinum-based chemotherapy. However, whether RET fusion NSCLC could benefit from immune checkpoint inhibitors (ICIs) remain unclear. This study retrospectively analyzed clinical outcomes of ICIs and RET inhibitors in RET fusion advanced NSCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
